TY - JOUR
T1 - Prognostic value of tumor budding in urothelial carcinoma : a meta-analysis and systematic review
AU - Shi, Ruoyu
AU - Tan, Mark Ting Le
AU - Lim, Gek Hsiang
AU - Du, Jingzeng
AU - Zhang, Limin
AU - Zeng, Lixia
AU - Tan, Puay Hoon
PY - 2023/6
Y1 - 2023/6
N2 - Recently, tumor budding (TB) has been suggested as a strong prognostic marker in urinary tract urothelial carcinoma (UC). The aim of this systematic review is to test the prognostic value of TB in UC by a meta-analysis of previously published studies. We systematically reviewed the literature related to TB by using the databases of Scopus, PubMed, and Web of Science. The search was limited to publications in the English language up to July 2022. There were 790 patients from 7 retrospective studies in which TB has been evaluated in UC. Two authors independently extracted the results from eligible studies. The meta-analysis of eligible studies revealed that TB is a significant prognosticator for progression-free survival in UC, with a hazard ratio (HR) of 3.51 (95% CI, 1.86-6.62; P <.001) in univariate analysis and a HR of 2.78 (95% CI, 1.57-4.93; P <.001) in multivariate analysis; a significant prognosticator for overall survival and cancer-specific survival in UC, with a HR of 3.07 (95% CI, 2.04-4.64; P <.001) and a HR of 2.18 (95% CI, 1.11-4.29; P =.02) respectively in univariate analysis. Our findings confirm that UC with a high TB count is at a high risk of progress. TB could be considered as an element in pathology reports and future oncologic staging systems.
AB - Recently, tumor budding (TB) has been suggested as a strong prognostic marker in urinary tract urothelial carcinoma (UC). The aim of this systematic review is to test the prognostic value of TB in UC by a meta-analysis of previously published studies. We systematically reviewed the literature related to TB by using the databases of Scopus, PubMed, and Web of Science. The search was limited to publications in the English language up to July 2022. There were 790 patients from 7 retrospective studies in which TB has been evaluated in UC. Two authors independently extracted the results from eligible studies. The meta-analysis of eligible studies revealed that TB is a significant prognosticator for progression-free survival in UC, with a hazard ratio (HR) of 3.51 (95% CI, 1.86-6.62; P <.001) in univariate analysis and a HR of 2.78 (95% CI, 1.57-4.93; P <.001) in multivariate analysis; a significant prognosticator for overall survival and cancer-specific survival in UC, with a HR of 3.07 (95% CI, 2.04-4.64; P <.001) and a HR of 2.18 (95% CI, 1.11-4.29; P =.02) respectively in univariate analysis. Our findings confirm that UC with a high TB count is at a high risk of progress. TB could be considered as an element in pathology reports and future oncologic staging systems.
UR - https://hdl.handle.net/1959.7/uws:78566
U2 - 10.1016/j.labinv.2023.100136
DO - 10.1016/j.labinv.2023.100136
M3 - Article
SN - 1530-0307
SN - 0023-6837
VL - 103
JO - Laboratory Investigation
JF - Laboratory Investigation
IS - 6
M1 - 100136
ER -
